28.02.2013 Views

The Principles of Clinical Cytogenetics - Extra Materials - Springer

The Principles of Clinical Cytogenetics - Extra Materials - Springer

The Principles of Clinical Cytogenetics - Extra Materials - Springer

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Index 583<br />

and intrauterine growth restriction,<br />

284<br />

and mosaic trisomy 10, 286<br />

and mosaic trisomy 8, 286<br />

and trisomy 18, 286<br />

and uniparental disomy, 285<br />

definition <strong>of</strong>, 283<br />

incidence <strong>of</strong> in amniocentesis, 284<br />

incidence <strong>of</strong> in chorionic villus sampling,<br />

284, 285, t285<br />

Plasma cell myeloma, t369, 397, 475<br />

14q32, 475<br />

17p13, f473, 475<br />

del(13)(q14), f470, f473, 475<br />

IGH, f473, 475<br />

TP53, f473, 475<br />

t(11;14), f473, 475<br />

t(14;14), 475<br />

t(4;16), 475<br />

Plasmacytoma, t369, 397<br />

Plus sign, 33, 35, 51<br />

PLZF, 382<br />

PML, 380, 382, t390, 467<br />

PML/RARα, 380, 381, 382<br />

POF (premature ovarian failure), 222–223,<br />

225, 503<br />

Pokeweed, 65<br />

Polar body, 25<br />

Poly(A) tail, 12<br />

Polycystic ovary syndrome, f248<br />

Polycythemia vera (PV), t368, 373<br />

Polysomy X syndromes, 215-219<br />

origin <strong>of</strong> extra chromosomes, 219<br />

Population doubling, 355<br />

Position effect, 170, 222, 223<br />

Postanalytical testing components, 103<br />

Potacki–Shaffer syndrome, t179<br />

Potassium chloride (KCl), 0.075 M, 68<br />

Prader–Willi syndrome, 175, t179, f180,<br />

196, t255, 458, f460, 518–519,<br />

528, 549<br />

contiguous gene syndrome, 519<br />

diagnosis, 519<br />

etiology, 518<br />

phenotype, 518<br />

Preanalytical testing components, 94<br />

Pregnancy-associated plasma protein-A<br />

(PAPP-A), 290, 303<br />

Pregnancy loss, t326<br />

chromosomally normal, 323, 327,<br />

337–338<br />

causes, 329, 337<br />

immunologic factors, 326, 337, 340<br />

lethal mutations, 337–338<br />

molar pregnancy, 334–336<br />

recurrence risk, 329<br />

developmental age, 324–326, 339<br />

incidence, 323–324<br />

infection and, 326, 340<br />

karyotype abnormalities<br />

and fetal anomalies, 326, 333,<br />

339–340<br />

and gestational age, 324–327<br />

incidence, 324–328, 339–340<br />

autosomal monosomy, 326, 328<br />

monosomy X, 327, 330–332<br />

mosaicism, 338<br />

triploidy, 334-335<br />

trisomy, 327-330<br />

mechanisms/types <strong>of</strong> errors, 327–328<br />

fertilization, 327, 334–336<br />

meiosis, 327, 328–332<br />

mitosis, 327, 332–333<br />

structural rearrangements/<br />

translocations, 327, 336–337<br />

translocations, 327, 336, 339<br />

patient concerns, 323, 341<br />

psycho-social aspects, 323<br />

recurrence risk, 328, 336–337, 340–341<br />

Preimplantation cytogenetics, 341<br />

Preimplantation genetic diagnosis (PGD),<br />

466<br />

Preimplantation genetic testing (PGT),<br />

503<br />

Preliminary reports, 103, 104<br />

Premature aging syndrome, 355<br />

Premature centromere separation, 354–355,<br />

f356<br />

Premature ovarian failure (POF), 222–223,<br />

225, 503

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!